logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5115.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5115.produseast1
Epicentre Scientific Day Paris 2023 | Collections | MSF Science Portal
Epicentre Scientific Day Paris 2023

Epicentre Scientific Day Paris 2023

Collection Content

Conference Material
|
Abstract

Epidemiological situation of cholera in 2023

Finger F
2023-06-08 • Epicentre Scientific Day Paris 2023
2023-06-08 • Epicentre Scientific Day Paris 2023
The years 2022 and 2023 have been marked by a number of cholera outbreaks affecting populations around the world. Hundreds of thousands of cholera cases and thousands of deaths have been...

See more collections

Snake envenoming: a neglected crisis

Snake envenoming: a neglected crisis

Every year 2 million or more people fall victim to snakebite envenoming, mostly in poor, rural communities of Africa, Asia and Latin America. Between 83,000—138,000 of them die, while hundreds of thousands more suffer debilitating long-term complications or disabilities.


Although some antivenom medicines are highly effective when used promptly and appropriately, many snakebite victims get no treatment at all. Those who do may receive antivenoms which don’t work against the type of snake that bit them, or were not rigorously tested for safety and effectiveness.


To mark World Snakebite Awareness Day on September 19th, the Collection linked below brings together recent MSF work on this highly neglected disease. Several articles and conference presentations help fill evidence gaps on the burden of disease and its impacts or on treatment outcomes with specific antivenoms in specific regions. Others examine how to tackle the formidable challenges of availability and affordability, the absence of regulatory oversight for making, testing and registering antivenoms, and the anemic R&D pipeline for new products—all of which impede access for patients to safe, effective treatment tailored to local snake species.

MSF logo

Homepage featured
No description available
The endTB project

The endTB project

The endTB project aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners Unitaid and the Transformational Investment Capacity (TIC) of MSF. This collection contains the final and intermediate results of the studies, advocacy reports, and study presentations. For more information about the endTB project, visit https://endtb.org/.

View All Collections